Cervical Cancer Development: Implications of HPV16 E6E7-NFX1-123 Regulated Genes.
E6
E7
HPV16
NFX1-123
cervical cancer
keratinocytes
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Dec 2021
08 Dec 2021
Historique:
received:
05
11
2021
revised:
01
12
2021
accepted:
03
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
High-risk human papillomavirus (HR HPV) causes nearly all cervical cancers, half of which are due to HPV type 16 (HPV16). HPV16 oncoprotein E6 (16E6) binds to NFX1-123, and dysregulates gene expression, but their clinical implications are unknown. Additionally, HPV16 E7's role has not been studied in concert with NFX1-123 and 16E6. HR HPVs express both oncogenes, and transformation requires their expression, so we sought to investigate the effect of E7 on gene expression. This study's goal was to define gene expression profiles across cervical precancer and cancer stages, identify genes correlating with disease progression, assess patient survival, and validate findings in cell models. We analyzed NCBI GEO datasets containing transcriptomic data linked with cervical cancer stage and utilized LASSO analysis to identify cancer-driving genes. Keratinocytes expressing 16E6 and 16E7 (16E6E7) and exogenous NFX1-123 were tested for LASSO-identified gene expression. Ten out of nineteen genes correlated with disease progression, including CEBPD, NOTCH1, and KRT16, and affected survival. 16E6E7 in keratinocytes increased CEBPD, KRT16, and SLPI, and decreased NOTCH1. Exogenous NFX1-123 in 16E6E7 keratinocytes resulted in significantly increased CEBPD and NOTCH1, and reduced SLPI. This work demonstrates the clinical relevance of CEBPD, NOTCH1, KRT16, and SLPI, and shows the regulatory effects of 16E6E7 and NFX1-123.
Identifiants
pubmed: 34944802
pii: cancers13246182
doi: 10.3390/cancers13246182
pmc: PMC8699269
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : R01 CA172742
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM130448
Pays : United States
Organisme : NCI NIH HHS
ID : R15 CA242057
Pays : United States
Références
Genes Dev. 2004 Sep 15;18(18):2269-82
pubmed: 15371341
Virology. 2019 May;531:171-182
pubmed: 30903928
J Virol. 2013 Dec;87(24):13741-50
pubmed: 24109236
Onco Targets Ther. 2020 Jun 26;13:6143-6156
pubmed: 32617009
Lancet. 2013 Sep 7;382(9895):877-87
pubmed: 23827089
Nucleic Acids Res. 2017 Jan 4;45(D1):D499-D506
pubmed: 28053164
N Engl J Med. 2003 Feb 6;348(6):518-27
pubmed: 12571259
Aging (Albany NY). 2018 Jan 20;10(1):13-14
pubmed: 29356683
Tumour Virus Res. 2021 Jun;11:200213
pubmed: 33716206
J Virol. 2009 Jul;83(13):6446-56
pubmed: 19369336
Methods. 1997 Aug;12(4):337-42
pubmed: 9245614
Lancet. 2011 Mar 12;377(9769):932-40
pubmed: 21367446
Biology (Basel). 2021 Mar 30;10(4):
pubmed: 33808060
New Microbiol. 2017 Apr;40(2):80-85
pubmed: 28368072
Rev Med Virol. 2015 Mar;25 Suppl 1:2-23
pubmed: 25752814
Cancer Lett. 2020 Feb 28;471:88-102
pubmed: 31812696
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19537-42
pubmed: 24218583
Semin Cancer Biol. 2014 Jun;26:13-21
pubmed: 24316445
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
J Virol. 2007 Apr;81(8):3786-96
pubmed: 17267499
Cancers (Basel). 2020 Dec 23;13(1):
pubmed: 33374731
PLoS Pathog. 2015 Mar 11;11(3):e1004712
pubmed: 25760330
PLoS One. 2017 Nov 8;12(11):e0187514
pubmed: 29117186
Clin Transl Med. 2020 Sep;10(5):e168
pubmed: 32997416
Virology. 2015 Apr;478:50-60
pubmed: 25723053
Viruses. 2019 Oct 09;11(10):
pubmed: 31600915
Cancer Lett. 2019 May 1;449:106-113
pubmed: 30776478
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Natl Cancer Inst. 2010 Mar 3;102(5):315-24
pubmed: 20157096
Nat Rev Cancer. 2010 Aug;10(8):550-60
pubmed: 20592731